# breast cancer - gpt-5.6-luna

- Benchmark system: E2seq + Agent RAG
- Repeat: 1
- Task type: PROGNOSIS
- Tissue / sample source: breast tumor tissue
- Comparison or endpoint: overall survival (OS)
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: OpenAI / gpt-5.6-luna
- Message SHA-256: 2eef237c25053f55d87c73e963368cae88b5c698447f11e7e98ebc594d62e5bb
- Response HTTP status: 200
- Prompt tokens: 15413
- Completion tokens: 5803
- Reasoning tokens: 0
- Total tokens: 21216
- API requests reported: 1
- Elapsed seconds: 157.732
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 685.605
- Question handoff seconds: 699.996
- Final benchmark system: E2seq; file rank 1/5; original repeat 1; model vendor: OpenAI

---
## Data-quality and interpretive warning

The uploaded results show a highly uniform statistical pattern: all 100 unique genes have **P ≤ 0.05 and FDR ≤ 0.01**, with 52 risk-associated genes and 48 protective-associated genes, despite generally modest HRs (approximately 1.18–1.26 or 0.79–0.84). The ledger also reports **106 retained rows, six duplicate/group rows**, although 100 unique genes are represented. This may reflect a very large sample size, correlated features, probe-level structure, or possible model/calibration issues. Therefore, the individual P values should not be interpreted as evidence that every gene is independently prognostic.

The results are prognostic associations, not disease-state differential expression results. Because no log2FC values are supplied, it is not possible to conclude that a risk-associated gene is transcriptionally “upregulated” or that a protective-associated gene is “downregulated.” **External statistical validation was not performed**: the retrieved databases and literature provide biological context but no independent-cohort OS statistic.

## 1. Overall biological interpretation

The strongest and most coherent signal is a **prognostically adverse proliferative and mitotic program**. Risk-associated genes include multiple components of mitotic progression, chromosome segregation, cytokinesis, and cell-cycle control, including **PKMYT1, RACGAP1, KIF20A, TROAP, CDCA5, TPX2, KIF4A, UBE2C, CDC20, AURKA, ZWINT, NUSAP1, UBE2S, and PRC1**. Their consistent HRs above 1 suggest that higher expression of this coordinated program is associated with poorer OS in the analyzed cohort.

A second major feature is a **protective immune-associated compartment**, represented by **FCER1A, CD1C, CD1E, FLT3, KLRB1, IL27RA, STAT5A, STAT5B, and JCHAIN**. In bulk breast-tumor tissue, this pattern may reflect immune infiltration or immune-state differences rather than tumor-cell-intrinsic protection.

A third pattern comprises **protective stromal, extracellular-matrix, and differentiated epithelial markers**, including **OGN, COL14A1, MFAP4, ADAMTS8, LAMA2, PDGFRA, RELN, COL17A1, CLDN11, TP63, and IGF1**. These may indicate tumor composition, stromal organization, epithelial differentiation, or a less aggressive tissue state. The data therefore support a model in which poor survival is associated with tumor proliferation and mitotic activity, whereas better survival is associated with immune and structural tissue features. Whether these are causal tumor programs or markers of tumor composition remains unresolved.

## 2. Core biological programs

### Program 1: Mitotic cell cycle, chromosome segregation, and cytokinesis

- **Direction:** Risk-associated.
- **Supporting genes:** **PKMYT1 HR=1.2437685**, **RACGAP1 HR=1.223506**, **KIF20A HR=1.2180492**, **CDCA5 HR=1.2179013**, **TPX2 HR=1.2017253**, **KIF4A HR=1.1985808**, **UBE2C HR=1.2100353**, **CDC20 HR=1.1912581**, **AURKA HR=1.1885146**, **ZWINT HR=1.1906277**, **NUSAP1 HR=1.1942371**, and **PRC1 HR=1.1859845**. All listed genes have FDR values between **2.186e-08 and 1.210179e-06**.
- **Relevant pathways:** **KEGG Cell cycle**; **GO: Positive Regulation of Mitotic Nuclear Division (GO:0045840)**; related Hallmark interpretation would be **E2F Targets** or **G2M Checkpoint**, although those Hallmark computations were not supplied.
- **Interpretation:** The number and functional coherence of risk-associated mitotic genes are more informative than any single gene. PKMYT1 is related to cell-cycle kinase control; AURKA and TPX2 are associated with spindle organization; CDC20, UBE2C, and UBE2S are components of ubiquitin-dependent cell-cycle progression; RACGAP1, KIF20A, and PRC1 are consistent with cytokinesis and cytoskeletal remodeling.
- **Evidence strength:** **Strong within-cohort program-level association.** The supplied pathway batch also identified cell-cycle-related terms, and STRING records connect subsets of these genes through PLK1, TPX2, ANAPC2, BUB1B, CDC20, and DLGAP5.
- **Limitations:** The pathway results were retrieved before synthesis and were not recomputed here; recurrence is not a new enrichment P value. STRING relationships may represent functional association, co-expression, or literature-derived evidence rather than direct physical binding. Proliferation signatures can also be confounded by tumor grade, stage, and tumor purity.

### Program 2: Ubiquitin-dependent cell-cycle control and mitotic checkpoint activity

- **Direction:** Risk-associated.
- **Supporting genes:** **UBE2C HR=1.2100353**, **CDC20 HR=1.1912581**, **UBE2S HR=1.1841829**, **PTTG1 HR=1.1974445**, **PRC1 HR=1.1859845**, **PKMYT1 HR=1.2437685**, and **AURKA HR=1.1885146**.
- **Relevant pathways:** **GO: Positive Regulation of Ubiquitin Protein Ligase Activity (GO:1904668)** and **GO: Positive Regulation of Ubiquitin-Protein Transferase Activity (GO:0051443)**; KEGG **Cell cycle**.
- **Interpretation:** This is related to, but conceptually narrower than, the general proliferation program. The convergence of APC/C-associated genes such as CDC20, UBE2C, and UBE2S with mitotic regulators suggests that dysregulated proteolytic timing and checkpoint release may accompany the adverse phenotype.
- **Evidence strength:** **Moderate-to-strong within-cohort association**, supported by multiple genes and the supplied ontology batch.
- **Limitations:** This may not be statistically independent from Program 1 because the same genes and underlying cell-cycle biology contribute to both signals. It should not be treated as a separately validated pathway without a formal gene-set analysis.

### Program 3: Immune and antigen-presenting-cell-associated tissue composition

- **Direction:** Protective-associated.
- **Supporting genes:** **FCER1A HR=0.7932319**, **CD1C HR=0.81422548**, **CD1E HR=0.82361278**, **FLT3 HR=0.81703284**, **KLRB1 HR=0.82162453**, **IL27RA HR=0.82546531**, **STAT5A HR=0.80627148**, **STAT5B HR=0.83716163**, and **JCHAIN HR=0.80290118**.
- **Relevant pathways:** Immune receptor signaling and antigen-processing/antigen-presentation categories would be biologically appropriate, but no formal immune-pathway enrichment result was supplied for this cohort.
- **Interpretation:** The coordinated protective association of dendritic-cell-associated genes, lymphocyte-associated genes, cytokine-receptor signaling genes, and JCHAIN is compatible with an immune-infiltrated tumor microenvironment or a more immune-active tumor state.
- **Evidence strength:** **Moderate within-cohort association; composition-sensitive.** The genes have immune/tissue annotations in external resources, and STRING includes a STAT3-centered association involving **FLT3, LEPR, STAT5A, and STAT5B**.
- **Limitations:** Bulk tumor RNA cannot distinguish immune-cell abundance from altered expression within tumor cells. The data do not demonstrate immune activation, antitumor immunity, or improved treatment response. JCHAIN may also reflect plasma-cell or immunoglobulin-related content, but the present data do not quantify that compartment.

### Program 4: Extracellular matrix, stromal organization, and tissue architecture

- **Direction:** Protective-associated.
- **Supporting genes:** **OGN HR=0.80743973**, **COL14A1 HR=0.82355765**, **MFAP4 HR=0.83417958**, **ADAMTS8 HR=0.7928718**, **LAMA2 HR=0.83003966**, **PDGFRA HR=0.83760447**, **RELN HR=0.79635886**, **OMD HR=0.8290976**, **RBP7 HR=0.83174472**, and **PROS1 HR=0.83621827**.
- **Relevant pathways:** GO extracellular-region and extracellular-matrix organization categories; no formal Reactome or GO enrichment P value was supplied.
- **Interpretation:** These genes collectively suggest differences in matrix composition, stromal cell states, vascular/perivascular organization, or tissue architecture. Their protective association may mark a less invasive tissue environment, but it could equally reflect a higher proportion of nonmalignant stromal cells.
- **Evidence strength:** **Moderate exploratory association**, supported by multiple extracellular and stromal annotations. The retrieved literature includes a breast-cancer study describing **PROS1** as a prognostic biomarker associated with immune infiltration (PMID: **37827342**), but that report is not an independent statistical validation of this cohort.
- **Limitations:** Stromal signatures are particularly vulnerable to tumor-purity and sampling effects. The data do not establish that matrix genes suppress invasion or improve survival.

### Program 5: Metabolic, translational, and stress-response biology

- **Direction:** Predominantly risk-associated for the selected representatives.
- **Supporting genes:** **LARP1 HR=1.2611983**, **STIP1 HR=1.2368966**, **GSK3B HR=1.2271421**, **ATP2A2 HR=1.2378678**, **CPT1A HR=1.1962357**, **GPI HR=1.1924932**, and **TRIB3 HR=1.1914433**.
- **Relevant pathways:** Broadly compatible with protein translation, metabolic adaptation, ER or cellular stress, and signaling; GSK3B annotations include ErbB, chemokine, and cell-cycle pathways. No formal pathway test for this specific grouping was supplied.
- **Interpretation:** LARP1 and STIP1 may reflect translational or proteostasis-related tumor states, while CPT1A and GPI are compatible with altered energy metabolism. GSK3B is a signaling kinase with links to WNT, metabolism, and cell-cycle biology. Together these genes suggest metabolic and stress adaptation accompanying the risk phenotype.
- **Evidence strength:** **Exploratory**, because this group is biologically heterogeneous and less sharply defined than the mitotic program.
- **Limitations:** These genes may be downstream correlates of proliferation, treatment exposure, hypoxia, or cellular stress rather than independent drivers of OS. External literature is mixed across tumor types and does not provide independent breast-cancer OS statistics here.

## 3. Key genes and interaction modules

| Candidate | Current association | Potential relevance | Relationship type and evidence |
|---|---:|---|---|
| **PKMYT1** | Risk; HR=1.2437685, FDR=9.7437879e-10 | Cell-cycle kinase control and mitotic progression | **Pathway co-membership and functional network association** with the cell-cycle module; a direct physical interaction with the other selected genes is not established by the supplied evidence. |
| **AURKA–TPX2 module** | AURKA HR=1.1885146; TPX2 HR=1.2017253 | Spindle assembly and mitotic progression | STRING reports a network relationship among **AURKA, TPX2, KIF4A, NUSAP1, and PRC1**. This should be described as **protein-interaction/network evidence where specifically recorded**, not assumed for every pair. |
| **CDC20–UBE2C–UBE2S module** | CDC20 HR=1.1912581; UBE2C HR=1.2100353; UBE2S HR=1.1841829 | Ubiquitin-dependent cell-cycle progression and checkpoint control | **Pathway co-membership and STRING functional association** involving ANAPC2 and CDC20-related records; not proof that all three proteins directly bind one another. |
| **RACGAP1–KIF20A–PRC1 module** | HRs=1.223506, 1.2180492, and 1.1859845 | Cytokinesis, spindle organization, and cytoskeletal remodeling | **Mitotic pathway co-membership and network association**; direct physical interaction is only claimed where a database specifically reports it. |
| **LARP1** | Risk; HR=1.2611983, FDR=4.4762322e-10 | Translational control and potentially proliferative tumor state | **Indirect/putative relationship** to proliferation and metabolic adaptation; the current dataset does not establish mechanism. |
| **GSK3B** | Risk; HR=1.2271421, FDR=1.1585489e-09 | Signaling, metabolism, WNT-related regulation, and cell-cycle biology | STRING reports high-confidence interactions with **CTNNB1, AXIN1/2, APC, BTRC, DVL1, and FRAT1**, representing **protein-network evidence**. These records do not prove that the prognostic association is mediated through WNT signaling. |
| **STIP1** | Risk; HR=1.2368966, FDR=9.7437879e-10 | Proteostasis, stress response, and tumor-state biology | The literature record PMID **37488801** reports association with tumor immune infiltration and prognosis in a pan-cancer analysis. This is **literature association**, not independent validation of the present breast-cancer cohort. |
| **CD1C–FCER1A–CD1E–FLT3 module** | Protective; HRs=0.81422548, 0.7932319, 0.82361278, and 0.81703284 | Antigen-presenting-cell-associated immune compartment | **Cell-type/co-expression and immune pathway association**; not evidence of direct physical interaction among all genes. |
| **STAT5A–STAT5B–IL27RA module** | Protective; STAT5A HR=0.80627148, STAT5B HR=0.83716163, IL27RA HR=0.82546531 | Cytokine-responsive immune signaling | STRING includes a STAT3-centered network involving FLT3, LEPR, STAT5A, and STAT5B. This is **regulatory/network context**, not proof of a causal STAT5 mechanism in these tumors. |
| **OGN–COL14A1–MFAP4–ADAMTS8 module** | Protective; HRs=0.80743973, 0.82355765, 0.83417958, and 0.7928718 | Matrix organization and stromal architecture | **Extracellular-matrix pathway co-membership and tissue-composition association**; direct interaction among these proteins is not established by the supplied records. |

## 4. Validation priorities

### 1. Validate the proliferation/mitotic signature as an OS biomarker  
**Classification:** Biomarker

- **Why prioritize it:** It is the most internally coherent risk-associated program, with many genes spanning mitosis, chromosome segregation, cytokinesis, and cell-cycle ubiquitin control.
- **Current evidence:** Multiple genes have consistent HRs above 1, including PKMYT1, RACGAP1, KIF20A, CDCA5, TPX2, UBE2C, CDC20, AURKA, and NUSAP1. The supplied pathway batch identified cell cycle and mitotic-nuclear-division categories.
- **External evidence:** STRING and pathway annotations support relationships among subsets of these genes. However, **external statistical validation was not performed**; no independent OS HR or FDR was supplied.
- **Next step:** Predefine a compact signature or pathway score, test it in an independent breast-cancer OS cohort, and adjust for stage, grade, subtype, treatment, age, and tumor purity.
- **Status:** **Supported hypothesis**, not clinically established.

### 2. Test whether the protective immune signal reflects immune-cell abundance  
**Classification:** Confounding or composition check

- **Why prioritize it:** The protective genes include CD1C, FCER1A, CD1E, FLT3, KLRB1, STAT5A/B, IL27RA, and JCHAIN, which could reflect variation in immune-cell composition.
- **Current evidence:** Coordinated HR<1 associations across several immune-associated genes.
- **External evidence:** Tissue and immune annotations support the cell-type interpretation, but they do not distinguish infiltration from tumor-cell-intrinsic expression or prove antitumor activity.
- **Next step:** Estimate immune and stromal fractions using established deconvolution methods, compare with pathology-based lymphocyte scores, and validate selected markers by multiplex immunohistochemistry or single-cell/spatial transcriptomics.
- **Status:** **Supported hypothesis** for composition; **insufficient evidence** for a causal protective immune mechanism.

### 3. Functionally test the mitotic kinase–spindle network  
**Classification:** Mechanistic hypothesis

- **Why prioritize it:** The risk-associated genes form a coherent biological axis involving PKMYT1, AURKA, TPX2, RACGAP1, KIF20A, and PRC1.
- **Current evidence:** Consistent risk associations and precomputed STRING network records, including TPX2-, PLK1-, and DLGAP5-related connections.
- **External evidence:** Functional annotations and interaction databases support mitotic roles, but database associations may combine physical interaction, co-expression, prediction, and literature evidence.
- **Next step:** Perturb these genes individually and in combinations in breast-cancer models, then measure proliferation, mitotic errors, cytokinesis failure, invasion, and treatment sensitivity.
- **Status:** **Supported hypothesis** for a functional mitotic module; causality is unproven.

### 4. Evaluate whether stromal architecture is an independent prognostic axis  
**Classification:** Confounding or composition check

- **Why prioritize it:** OGN, COL14A1, MFAP4, ADAMTS8, LAMA2, PDGFRA, RELN, and related genes show coordinated protective associations.
- **Current evidence:** Multiple HRs below 1 and extracellular-region annotations.
- **External evidence:** PROS1 has been reported in a breast-cancer bioinformatics and experimental study as a prognostic biomarker associated with immune infiltration (PMID: **37827342**). This is supportive contextual literature, not independent cohort replication.
- **Next step:** Adjust the prognostic model for tumor purity and stromal scores, then validate matrix and vascular compartments histologically and spatially.
- **Status:** **Exploratory hypothesis** until composition-adjusted and independent-cohort analyses are performed.

### 5. Investigate LARP1/STIP1/GSK3B as context-dependent risk markers rather than immediate therapeutic targets  
**Classification:** Therapeutic target

- **Why prioritize it:** These genes have among the stronger risk associations in the table: LARP1 HR=1.2611983, STIP1 HR=1.2368966, and GSK3B HR=1.2271421.
- **Current evidence:** Strong within-cohort associations and plausible links to translation, stress, signaling, and cell-cycle biology.
- **External evidence:** STIP1 has been associated with prognosis and immune infiltration in a pan-cancer literature record (PMID: **37488801**), while GSK3B has curated signaling and interaction annotations. These are not evidence that inhibiting either gene improves breast-cancer OS. Drug or clinical-trial records, where present, indicate tractability or investigation, not therapeutic efficacy.
- **Next step:** Test dependence in molecularly defined breast-cancer models, assess normal-tissue toxicity, and determine whether effects remain after controlling for proliferation and subtype.
- **Status:** **Exploratory hypothesis**; not an established therapeutic target.

## 5. Evidence grounding and conflicts

- **Direct cohort evidence:** The uploaded survival table is the only source of statistical evidence. It reports 100 unique genes, 52 risk-associated and 48 protective-associated, all meeting the supplied nominal and FDR thresholds.
- **Pathway/ontology evidence:** The precomputed batch supports cell cycle, mitotic nuclear division, ubiquitin-ligase activity, extracellular region, plasma membrane, ATP binding, and RNA binding. These are contextual annotations; no new enrichment calculation was performed during synthesis.
- **Network evidence:** STRING records support functional or protein-network relationships, including PLK1-, TPX2-, CDC20-, BUB1B-, CDK4-, and DLGAP5-related modules. Relationship type is source-dependent and should not be generalized to direct physical interaction.
- **Tissue and disease evidence:** Immune and stromal annotations make the protective modules biologically plausible in bulk breast-tumor tissue. They do not establish tumor-cell autonomy or causality.
- **Literature evidence:** PMID **37827342** supports the plausibility of PROS1 as a breast-cancer prognostic/immune-associated marker, and PMID **37488801** provides pan-cancer context for STIP1. These studies may use related public datasets or overlapping annotation sources and are not independent statistical validation of this analysis.
- **Independent validation:** No external cohort, endpoint-specific HR, P value, FDR, model, or study was supplied. Thus, **external statistical validation was not performed**.
- **Conflicts:** The main apparent tension is biological rather than statistical: proliferation-associated genes are risk-associated, while immune and stromal genes are protective-associated. This is compatible with tumor heterogeneity, but it also raises the possibility that the result is partly driven by differences in cellular composition rather than opposing tumor-cell programs.

## 6. Major limitations and alternative explanations

1. **Potentially overconfident statistical calibration:** Uniformly significant results and modest, similarly sized HRs across 100 genes may reflect a very large cohort, correlated predictors, probe duplication, or model instability. Recheck sample size, event count, proportional-hazards assumptions, expression scaling, probe collapsing, and multiple-testing procedures.

2. **Tumor purity and cell composition:** Immune and stromal protective signals may arise from variable proportions of immune, fibroblast, endothelial, or epithelial cells. Investigate with purity estimates, deconvolution, pathology review, and single-cell or spatial data.

3. **Proliferation confounding by disease severity:** The mitotic program may primarily encode grade, stage, subtype, or tumor burden. Test whether the associations persist after multivariable adjustment and evaluate calibration in clinically defined subgroups.

4. **Treatment and clinical covariates:** OS associations may depend on treatment exposure, age, stage, subtype, recurrence status, and comorbidities. Without these covariates, prognostic associations cannot be interpreted as treatment-predictive or causal.

5. **Correlation and redundancy among genes:** Many cell-cycle genes are strongly co-expressed, so individual HRs may not represent independent effects. Use penalized or pathway-level models, bootstrap stability analysis, and external validation rather than interpreting the full 100-gene set as 100 independent discoveries.

Overall, the most defensible interpretation is that this cohort contains a strong **risk-associated mitotic/proliferative signature** alongside **protective immune- and stromal-associated signals**, but independent-cohort validation, composition adjustment, and mechanistic experiments are required before these findings can be considered generalizable or clinically actionable.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=64, external claims checked=0, external mismatches=0, status=passed.

Answer model API: OpenAI / gpt-5.6-luna

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 100/100 selected items (records returned); cbioportal 100/100 selected items (records returned); chembl 52/100 selected items (records returned); civic 12/100 selected items (records returned); clinicaltrials 57/100 selected items (records returned); clinvar 100/100 selected items (records returned); ensembl 100/100 selected items (records returned); europepmc 990 articles / initial full-cohort RAG 100 queries + 4 current-round queries; gtex 98/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 99/100 selected items (records returned); humanbase 100/100 selected items (records returned); intact 99/100 selected items (partially returned; some queries failed); mygene 100/100 selected items (records returned); omnipath 65/100 selected items (records returned); opentargets 100/100 selected items (records returned); pubmed 791 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 99/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 100/100 selected items (records returned)
Local databases: gutmgene 4/100 selected items (records returned); hmdb 31/100 selected items (records returned); string 100/100 selected items (records returned); trrust 40/100 selected items (records returned)
